SEC 13F Intelligence

Managers / Q2 2019 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$836M
Q2 2019
Positions
92
Filings on Record
30
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Sectoral Asset Management Inc reported $836M in U.S.-listed holdings across 92 positions for Q2 2019.

Its largest position, SWAVUSD, represents 5.8% of the portfolio.

Compared with Q1 2019, the fund opened 6 new positions and exited 20.

Portfolio Metrics

Turnover
+15.8%
vs prior filed quarter
Top-10 Concentration
+38.7%
share of reported value
Largest Position
+5.8%
Shockwave Medical
New / Exited
6 / 20
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.3%Other: 10.2%ADR: 2.5%
  • Common Stock · 87.3% · $730M
  • Other · 10.2% · $86M
  • ADR · 2.5% · $21M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ALXNALEXION PHARM INCNEW+73.2K73.2K+$10M$10M
CHNGUSDCHANGE HEALTHCARE INNEW+450.6K450.6K+$7M$7M
IMMUIMMUNOMEDICS INCNEW+418.9K418.9K+$6M$6M
TOCAGEN INCNEW+670.0K670.0K+$4M$4M
PHASEURPHASEBIO PHARMACEUTICALSNEW+176.0K176.0K+$2M$2M
UNIQURE N.V.NEW+14.5K14.5K+$1M$1M
FGENEURFIBROGEN INCADDED+221.4K302.7K+$9M$14M
2655787DBLUEPRINT MEDICINESADDED+6.8K11.0K+$701,000$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SWAVUSDSHOCKWAVE MEDICALhistory →COM5.80%$49M849.8K
2AM6AMICUS THERAPEUTICShistory →COM4.96%$41M3.32M
3APLSUSDAPELLIS PHARMACEUTICALShistory →COM4.51%$38M1.49M
4ARRYEURARRAY BIOPHARMA INChistory →COM4.40%$37M794.9K
5TDOCTELADOC HEALTHhistory →COM4.07%$34M513.2K
6ALNYALNYLAM PHARMACEUTICALShistory →COM3.49%$29M402.6K
7AERIEURAERIE PHARMACEUTICALShistory →COM3.38%$28M956.0K
8GILDGILEAD SCIENCES INChistory →COM3.22%$27M398.0K
9TNDMTANDEM DIABETES CAREhistory →COM2.47%$21M319.9K
10PTCTPTC THERAPEUTICS Ihistory →COM2.42%$20M450.6K
11RARXEURRA PHARMACEUTICALShistory →COM2.39%$20M665.7K
12PTLAEURPORTOLA PHARMACEUTICALShistory →COM2.34%$20M721.6K
13SRPTSAREPTA THERAPEUTICShistory →COM2.13%$18M117.1K
14NVSNNOVARTIS AGhistory →SPONSORED ADR1.99%$17M182.6K
15HRCHILL-ROM HLDS INChistory →COM1.99%$17M158.8K
16PFEPFIZER INChistory →COM1.88%$16M362.9K
17COLLCOLLEGIUM PHARMACEUTICALhistory →COM1.85%$15M1.17M
18LJPCLA JOLLA PHARMACEUTICALhistory →COM1.83%$15M1.66M
19WRIGHT MED GROUP N VORD SHS1.82%$15M511.2K
20MRKMERCK & CO INChistory →COM1.67%$14M166.8K
21FGENEURFIBROGEN INChistory →COM1.64%$14M302.7K
22RCMEURR1 RCM INChistory →COM1.62%$14M1.08M
23BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.57%$13M153.1K
24ALLERGAN PLCSHS1.57%$13M78.3K
25VCRAUSDVOCERA COMMUNICATIONShistory →COM1.46%$12M381.6K
26GBTUSDGLOBAL BLOOD THERAPEUTICShistory →COM1.42%$12M226.2K
27LLYLILLY ELI & COhistory →COM1.41%$12M106.7K
28ATRCATRICURE INChistory →COM1.38%$12M387.2K
29ASSEMBLY BIOSCIENCESCOM1.37%$11M847.7K
30XLRNACCELERON PHARMAhistory →COM1.32%$11M269.4K
31EVHEVOLENT HEALTH INChistory →COM1.29%$11M1.36M
32STMLEURSTEMLINE THERAPEUTICShistory →COM1.22%$10M666.2K
33HMSYHMS HOLDINGS CORPhistory →COM1.21%$10M311.3K
34BSXBOSTON SCIENTIFIChistory →COM1.16%$10M226.6K
35BMYBRISTOL MYERS SQUIBBhistory →COM1.16%$10M214.7K
36ALXNALEXION PHARM INChistory →COM1.15%$10M73.2K
37VRAYQVIEWRAY INChistory →COM1.13%$9M1.07M
38BDQMALBIREO PHARMA INCCOM0.94%$8M243.0K
39MEDTRONIC PLCSHS0.90%$7M76.9K
40CICIGNA CORPCOM0.89%$7M47.3K
41INSPINSPIRE MED SYS INCCOM0.88%$7M120.9K
42OBSEVA SACOM0.87%$7M643.2K
43ABTABBOTT LABSCOM0.84%$7M83.2K
44FTSVEURFORTY SEVEN INCCOM0.83%$7M656.7K
45VRTXVERTEX PHARMACEUTICALSCOM0.83%$7M37.8K
46IRTCIRHYTHM TECHNOLOGIESCOM0.82%$7M86.6K
47GLYCEURGLYCOMIMETICS INCCOM0.79%$7M552.8K
48CHNGUSDCHANGE HEALTHCARE INCOM0.79%$7M450.6K
49MEIRAGTX HLDINGS PLCCOM0.73%$6M225.9K
50EVELO BIOSCIENCESCOM0.72%$6M669.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.